Jinbosen Bio structures development around the decision a partner needs to make—whether a formulation approach is feasible, which attributes matter, how a candidate can be improved, or what evidence is needed for the next stage.
The workflow connects therapeutic-molecule properties and delivery barriers with formulation composition, nanoscale structure, biological interaction and translational requirements. Projects may use one module or progress through several.
Define the payload, intended route, target product profile, known failure modes and practical constraints. This frames the formulation hypothesis and identifies the smallest informative first study.
Typical decision: Is there a credible formulation route worth screening?
Compare selected compositions, excipients and process approaches using a structured plan. Screening focuses on attributes relevant to the payload rather than testing a broad platform without a decision framework.
Typical decision: Which candidates and variables warrant deeper evaluation?
Examine particle size, PDI, surface charge, morphology, payload association or encapsulation, integrity, release and stability as appropriate. Measurements are interpreted as a connected attribute set.
Typical decision: Does the formulation have a coherent and reproducible quality profile?
Use fit-for-purpose studies to investigate formulation stability, barrier interaction, cell association, uptake, permeability or compatibility where relevant. Results are used to refine formulation questions, not as stand-alone therapeutic claims.
Typical decision: Which formulation attributes are associated with the required in vitro behaviour?
Evaluate how preparation sequence, mixing, concentration, material handling and scale can influence critical quality attributes. The objective is a more reproducible and practical process—not simply a larger batch.
Typical decision: Can the selected formulation be prepared with adequate robustness?
Bring formulation, analytical, stability and process evidence together to identify remaining risks, next-stage studies and development priorities. The plan is shaped around the partner's programme and decision pathway.
Typical decision: What evidence and controls are needed for the next development stage?
Early projects need clarity and speed; later projects need stronger control of quality attributes, analytical interpretation and process reproducibility. Scope and documentation can be aligned with the immediate BD or R&D decision.
A defined hypothesis, success criteria and study sequence reduce unfocused experimentation and make outcomes easier to interpret.
Data packages can be organised around candidate selection, formulation optimisation, platform evaluation or readiness for further development.
Results are considered alongside remaining technical risks, manufacturability and the additional evidence required for translation.
A non-confidential introduction can be brief. Useful context includes the payload class, intended route, current formulation, known stability or delivery constraints, available material and the decision the study should support.
We can shape a focused feasibility, optimisation or development project around the evidence your team needs.
